Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 2
1990 9
1991 30
1992 38
1993 36
1994 49
1995 48
1996 64
1997 67
1998 83
1999 84
2000 45
2001 71
2002 67
2003 74
2004 75
2005 79
2006 97
2007 98
2008 85
2009 83
2010 96
2011 93
2012 76
2013 91
2014 85
2015 86
2016 76
2017 45
2018 50
2019 44
2020 47
2021 45
2022 35
2023 27
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

2,031 results

Results by year

Filters applied: . Clear all
Page 1
The salmeterol anomaly and the need for a urine threshold.
Jacobson GA, Hostrup M. Jacobson GA, et al. Drug Test Anal. 2022 Jun;14(6):997-1003. doi: 10.1002/dta.2810. Epub 2020 Jun 8. Drug Test Anal. 2022. PMID: 32314556
Salmeterol is a long acting beta2-agonist (LABA) used widely for the treatment of airways disease. There is evidence that beta2-agonists, including salmeterol, have the potential for performance enhancing effects when delivered at supratherapeutic dose …
Salmeterol is a long acting beta2-agonist (LABA) used widely for the treatment of airways disease. There is evidence that beta …
Pharmacological basis for duration of effect: formoterol and salmeterol versus short-acting beta 2-adrenoceptor agonists.
Lindén A, Rabe KF, Löfdahl CG. Lindén A, et al. Lung. 1996;174(1):1-22. doi: 10.1007/BF00167947. Lung. 1996. PMID: 8746998 Review.
The mechanisms behind the long duration of bronchodilating action of the beta 2-adrenoceptor agonists formoterol and salmeterol are only partially understood. This review compares pharmacological characteristics of long-acting versus short-acting beta 2-adrenoceptor …
The mechanisms behind the long duration of bronchodilating action of the beta 2-adrenoceptor agonists formoterol and salmeterol …
Salmeterol Xinafoate.
Anwar MM, El-Haggar RS, Zaghary WA. Anwar MM, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:321-69. doi: 10.1016/bs.podrm.2015.02.002. Epub 2015 Apr 1. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051688 Review.
Salmeterol xinafoate is a potent and a long-acting beta2-adrenoceptor agonist. ...Physical characteristics of salmeterol xinafoate were confirmed via: X-ray powder diffraction pattern, thermal analysis and UV, vibrational, nuclear magnetic reson …
Salmeterol xinafoate is a potent and a long-acting beta2-adrenoceptor agonist. ...Physical characteristics of salmet …
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
Ismaila AS, Haeussler K, Czira A, Tongbram V, Malmenäs M, Agarwal J, Nassim M, Živković-Gojović M, Shen Y, Dong X, Duarte M, Compton C, Vogelmeier CF, Halpin DMG. Ismaila AS, et al. Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20. Adv Ther. 2022. PMID: 35857184 Free PMC article.
INTRODUCTION: Few randomised controlled trials (RCTs) have directly compared long-acting muscarinic antagonist/long-acting beta(2)-agonist (LAMA/LABA) dual maintenance therapies for patients with chronic obstructive pulmonary disease (COPD). ...There are two different type …
INTRODUCTION: Few randomised controlled trials (RCTs) have directly compared long-acting muscarinic antagonist/long-acting beta(2)-agonis …
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events.
O'Shea O, Stovold E, Cates CJ. O'Shea O, et al. Cochrane Database Syst Rev. 2021 Apr 14;4(4):CD007694. doi: 10.1002/14651858.CD007694.pub3. Cochrane Database Syst Rev. 2021. PMID: 33852162 Free PMC article.
However, an increase in serious adverse events with the use of both regular formoterol and regular salmeterol (long-acting beta2-agonists) compared with placebo for chronic asthma has been demonstrated in previous Cochrane Reviews. ...Among adult and adolescent stud …
However, an increase in serious adverse events with the use of both regular formoterol and regular salmeterol (long-acting beta2-a …
Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma.
Bullone M, Vargas A, Elce Y, Martin JG, Lavoie JP. Bullone M, et al. Sci Rep. 2017 Aug 18;7(1):8843. doi: 10.1038/s41598-017-09414-8. Sci Rep. 2017. PMID: 28821845 Free PMC article.
Severely asthmatic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen avoidance for 12 weeks. ...Fluticasone/salmeterol and fluticasone monotherapy equally reverse peripheral airway smooth muscle remodel …
Severely asthmatic horses (6 horses/group) were treated with fluticasone, salmeterol, fluticasone/salmeterol, or with antigen …
beta2-agonists and acute respiratory distress syndrome.
Budinger GR, Mutlu GM. Budinger GR, et al. Am J Respir Crit Care Med. 2014 Mar 15;189(6):624-5. doi: 10.1164/rccm.201401-0170ED. Am J Respir Crit Care Med. 2014. PMID: 24628310 Free PMC article. No abstract available.
Salmeterol-Fluticasone: The Role Revisited.
Vora A, Dhar R, Pinto L, Koul P, Gaonkar P. Vora A, et al. J Assoc Physicians India. 2022 Dec;69(12):11-12. J Assoc Physicians India. 2022. PMID: 35057598
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatment with a combination of inhaled corticosteroids (ICS)/ long-acting beta-agonists (LABA); several studies have shown improvement in t …
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatme …
Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol.
Pitrez PM, Nanthapisal S, Castro APBM, Teli C, P G A. Pitrez PM, et al. BMJ Open Respir Res. 2023 Aug;10(1):e001706. doi: 10.1136/bmjresp-2023-001706. BMJ Open Respir Res. 2023. PMID: 37620110 Free PMC article. Review.
BACKGROUND: Fluticasone propionate/salmeterol xinafoate (FP/SAL) is an inhaled corticosteroid (ICS) and long-acting beta(2)-agonist (LABA) combination, indicated for the regular treatment of children (aged >4 years) with asthma that is inadequately control …
BACKGROUND: Fluticasone propionate/salmeterol xinafoate (FP/SAL) is an inhaled corticosteroid (ICS) and long-acting beta(2)- …
2,031 results